Related Experiment Video
Updated: May 24, 2026
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Roles of activated microglia in hypoxia induced neuroinflammation in the developing brain and the retina
Charanjit Kaur1, Gurugirijha Rathnasamy, Eng-Ang Ling
1Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, 4 Medical Drive, MD10, Singapore 117597, Singapore. antkaurc@nus.edu.sg
Abstract:
Amoeboid microglial cells (AMCs) in the developing brain display surface receptors and antigens shared by the monocyte-derived tissue macrophages. Activation of AMCs in the perinatal brain has been associated with periventricular white matter damage in hypoxic-ischemic conditions. The periventricular white matter, where the AMCs preponderate, is selectively vulnerable to hypoxia as manifested by death of premyelinating oligodendrocytes and degeneration of axons leading to neonatal mortality and long-term neurodevelopmental deficits. AMCs respond vigorously to hypoxia by producing excess amounts of inflammatory cytokines e.g. the tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) along with glutamate, nitric oxide (NO) and reactive oxygen species which collectively cause oligodendrocyte death, axonal degeneration as well as disruption of the immature blood brain barrier. A similar phenomenon is observed in the hypoxic developing cerebellum in which activated AMCs induced Purkinje neuronal death through production of TNF-α and IL-1β via their respective receptors. Hypoxia is also implicated in retinopathy of prematurity in which activation of AMCs has been shown to cause retinal ganglion cell death through production of TNF-α and IL-1β and NO. Because AMCs play a pivotal role in hypoxic injuries in the developing brain affecting both neurons and oligodendrocytes, a fuller understanding of the underlying molecular mechanisms of microglial activation under such conditions would be desirable for designing of a novel therapeutic strategy for management of hypoxic damage.
Insights
Amoeboid microglial cells (AMCs) in the developing brain become activated during hypoxia, releasing inflammatory factors that damage oligodendrocytes and axons. Understanding AMC activation is key to treating hypoxic brain injury in neonates.
Area of Science:
- Neuroscience
- Immunology
- Developmental Biology
Background:
- Amoeboid microglial cells (AMCs) in the developing brain share characteristics with monocyte-derived macrophages.
- AMC activation in perinatal hypoxic-ischemic conditions is linked to periventricular white matter damage.
Purpose of the Study:
- To investigate the role of AMCs in hypoxic brain injury.
- To elucidate the molecular mechanisms of AMC activation in response to hypoxia.
- To identify potential therapeutic targets for hypoxic damage in the developing brain.
Main Methods:
- The study reviews existing literature on AMC activation and hypoxic injury.
- It analyzes the molecular pathways involved in AMC response to hypoxia.
- It discusses the impact of AMC-derived factors on neural cells and the blood-brain barrier.
Main Results:
- Hypoxia triggers vigorous AMC activation, leading to the release of inflammatory cytokines (TNF-α, IL-1β), glutamate, nitric oxide (NO), and reactive oxygen species.
- These factors cause oligodendrocyte death, axonal degeneration, and blood-brain barrier disruption in the periventricular white matter.
- Similar mechanisms are observed in hypoxic injury to the cerebellum and retina, affecting Purkinje neurons and retinal ganglion cells, respectively.
Conclusions:
- AMCs play a critical role in hypoxic injuries affecting neurons and oligodendrocytes in the developing brain.
- Understanding AMC activation mechanisms is crucial for developing therapeutic strategies against neonatal hypoxic damage.
- Targeting AMC activation pathways may offer novel treatments for conditions like periventricular white matter damage and retinopathy of prematurity.
